Back to search results

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Essential Thrombocythemia (ET) · Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) · Myeloproliferative Neoplasms (MPN)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • St. Vincent's Hospital Sydney Limited, Sydney, New South Wales, Australia

  • Macquarie University, Sydney, New South Wales, Australia

  • Royal Adelaide Hospital, Adelaide, South Australia, Australia

  • St Vincent's Hospital (Melbourne), Melbourne, Victoria, Australia

  • Monash Medical Centre, Melbourne, Victoria, Australia

  • The Perth Blood Institute Limited, Perth, Western Australia, Australia

  • Hollywood Private Hospital, Nedlands, Australia

    Contact: Study coordinator (Andrew McQuillan) · andrew@qmedical.com.au · +61 893861811
    Contact: Principal Investigator (Andrew McQuilan)
View source on ClinicalTrials.gov(opens in a new tab)